Detecting molecular abnormalities in glioma exosomes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot study aims to evaluate the effectiveness of analyzing molecular abnormalities in exosomes derived from glioblastomas compared to the standard Foundation One Liquid CDx test. Gliomas, the most common primary brain tumors in adults, present challenges in diagnosis and management due to their heterogeneity. By utilizing next-generation sequencing (NGS) to profile circulating exosomes, the study seeks to provide more reliable and sensitive results for characterizing gliomas. Blood samples will be collected from eligible patients to assess the molecular alterations present in their tumors.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Subject of both sexes at least 18 years of age with glioblastoma.
* Patient for whom an FMI test is indicated, progressing after a 1st line following the chemotherapy and radiotherapy protocol (STUPP protocol)
* Patient affiliated to French social security

Exclusion Criteria:

* Patient included in another research protocol using an experimental molecule.
* Any medical or psychiatric condition which, in the Investigator's opinion, would preclude the patient from adhering to the protocol or completing the study per protocol
* Patient under legal protection, guardianship or curatorship
* Patient with active malignancy or a previous malignancy within the past 5 years; except for patient with resected Basocarcinoma and resected carcinoma in-situ of the cervix.

Where it's running

• CHU de Limoges
  Limoges, France Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• YN003 injection in glioma patients

  This phase 1 study tests whether YN003 injected IV is safe and tolerable for adults with recurrent or progressive glioma, and to explore how the drug behaves in the body and any early signs of activity.

  Recruiting at 2 sites Phase 1 Beijing Inno Medicine Co., Ltd. · Los Angeles, California and 4 other locations · NCT07929909

• Brain connectome project in adults with brain glioma undergoing surgery

  This registry collects MRI data and clinical information from adults with glioma to see how brain networks relate to surgery and recovery.

  Recruiting Northwell Health · New York, New York · NCT07927595

• Proton vs. Photon Radiation for Certain Grade 2–3 Gliomas

  This study tests whether proton therapy can better preserve thinking and memory than photon therapy for adults with IDH-mutated grade 2–3 gliomas who need radiation.

  Recruiting at 2 sites University Hospital, Essen · Essen and 1 other locations · NCT07750457

• Connectome-guided network planning for brain tumor surgery in eloquent areas

  This study tests whether using patient-specific brain network maps from diffusion MRI can help surgeons plan and guide brain tumor removal in eloquent areas.

  Recruiting ARNAS Civico Di Cristina Benfratelli Hospital · Palermo, PA · NCT07717827

• AI-powered analysis of brain MRI to help glioma care

  Doctors will use AI to study existing MRI scans and patient data from adults with glioma to see if it can help with non-invasive diagnosis and treatment planning.

  Recruiting Università degli Studi di Trento · Trento · NCT07703761

• Safusidenib in IDH1-mutant glioma after vorasidenib progression

  This trial tests safusidenib in people with IDH1-mutant glioma who progressed on vorasidenib and did not need immediate chemo or radiation.

  Recruiting at 2 sites Phase 2 Nuvation Bio Inc. · Los Angeles, California and 11 other locations · NCT07703436

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.